Casey C. Kopczynski
2017
In 2017, Casey C. Kopczynski earned a total compensation of $2M as Chief Scientific Officer at Aerie Pharmaceuticals, a 63% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $186,966 |
|---|---|
| Option Awards | $1,267,404 |
| Salary | $359,550 |
| Stock Awards | $195,231 |
| Total | $2,009,151 |
Kopczynski received $1.3M in option awards, accounting for 63% of the total pay in 2017.
Kopczynski also received $187K in non-equity incentive plan, $359.6K in salary and $195.2K in stock awards.
Rankings
In 2017, Casey C. Kopczynski's compensation ranked 5,486th out of 14,666 executives tracked by ExecPay. In other words, Kopczynski earned more than 62.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,486 out of 14,666 | 63rd |
Division Manufacturing | 1,974 out of 5,768 | 66th |
Major group Chemicals And Allied Products | 596 out of 2,074 | 71st |
Industry group Drugs | 458 out of 1,730 | 74th |
Industry Biological Products, Except Diagnostic Substances | 85 out of 316 | 73rd |
Source: SEC filing on April 27, 2018.
Kopczynski's colleagues
We found three more compensation records of executives who worked with Casey C. Kopczynski at Aerie Pharmaceuticals in 2017.
News
Aerie Pharmaceuticals CEO Vicente Anido's 2021 pay rises 4% to $3.8M
April 26, 2022
Aerie Pharmaceuticals CEO Vicente Anido's 2020 pay falls 35% to $3.6M
April 27, 2021
Aerie Pharmaceuticals CEO Vicente Anido's 2019 pay slips 18% to $5.5M
April 24, 2020
Aerie Pharmaceuticals CEO Vicente Anido's 2018 pay falls 33% to $6.8M
April 10, 2019